Trial Profile
Evaluation of the safety and efficacy of sorafenib therapy after TACE for unresectable hepatocellular carcinoma (multicenter study).
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Dec 2012
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms i-STEP
- 15 Oct 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan
- 14 Oct 2011 Additional lead trial investigator identified as reported by University Hospital Medical Information Network - Japan.
- 06 Oct 2011 New trial record